Bio-Techne announces investment in Wilson Wolf.
Minneapolis / February 24, 2023 (Local U.S. Time)
Bio-Techne Corporation (NASDAQ: TECH) announced that the newly finalized Local Coverage Determination (LCD) from National Government Services, Inc., a Medicare administrative contractor, includes coverage for ExoDx (the prostate test from Exosome Diagnostics, a Bio-Techne brand).
The updated policy includes an annual ExoDx prostate test for men who are already negative on biopsy but are considered at high risk for prostate cancer and are considering re-biopsy. The coverage will be effective from March 1, 2023.
For more details, please refer to the related links.

Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration
Related Links
Press Release




